Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-10-15
2010-06-22
Canella, Karen A (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387700, C530S387900, C530S388100, C530S388800, C530S388850
Reexamination Certificate
active
07741447
ABSTRACT:
The present invention relates to a method of detecting cancer by use of an oncogene, a method of screening for an active compound useful to treat and/or prevent cancer, and a pharmaceutical composition for treatment and/or prevention of cancer. More specifically, the present invention provides a method of detecting cancer based on the expression of the human oculospanin gene as a marker and a pharmaceutical composition containing an antibody capable of specifically recognizing human oculospanin and having cytotoxic activity against cancer cells.
REFERENCES:
patent: 5331573 (1994-07-01), Balaji et al.
patent: 5728821 (1998-03-01), Yelton et al.
patent: 5792456 (1998-08-01), Yelton et al.
patent: 2003/0124579 (2003-07-01), Mack et al.
patent: 2003/0228319 (2003-12-01), Frantz et al.
patent: 2004/0151665 (2004-08-01), Young et al.
patent: 2004/0180002 (2004-09-01), Young et al.
patent: 2004/0197328 (2004-10-01), Young et al.
patent: 2004/0258693 (2004-12-01), Young et al.
patent: 2005/0170368 (2005-08-01), Ashkenazi et al.
patent: 2007/0042360 (2007-02-01), Afar et al.
patent: 2007/0212735 (2007-09-01), Ashkenazi et al.
patent: WO 99/58515 (1999-11-01), None
patent: WO 01/09187 (2001-02-01), None
patent: WO03/088808 (2003-10-01), None
Clark (Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, 1993, pp. 4-5).
Campbell (Monoclonal Antibody Technology, 1984, pp. 1-32).
Fu et al. EMBO Journal, 1996, vol. 15 ,pp. 4392-4401.
Brennan et al. Journal of Autoimmunity, 1989, vol. 2, supp. pp. 177-186.
Zimmer. Cell Motility and the Cytoskeleton, 1991, vol. 20, pp. 325-337.
Eriksson et al. Diabetologia, 1992, vol. 35, pp. 143-147.
Dillman. Annals of Internal medicine, 1989, 111:592-603.
Gura. 1997, Science 278: 1041-1042.
Tockman et al. Cancer Res., 1992, 52:2711s-2718s.
Wistow et al. “Expressed sequence tag analysis of human RPE/choroid for the NEIBank Project: over 6000 non-redundant transcripts, novel genes and splice variants”, Molecular Vision 2002(8): pp. 205-220, Jun. 15, 2002.
Mammalian Gene Collection Program Team (contributed by Francis S. Collins), “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences,” PNAS 99(26): pp. 16899-16903, Dec. 24, 2002.
Longo et al., “Regulatory role of tetraspanin CD9 in tumorendothelial cell interaction during transendothelial invasion of melanoma cells,” Blood 98(13): pp. 3717-3726, Dec. 15, 2001.
Azorsa et al. “A general approach to the generation of monoclonal antibodies against members of the tetraspanin superfamily using recombinant GST fusion proteins,” Journal of Immunological Methods 229: pp. 35-48, 1999.
Roitt et al. Immunology, 1993, Mosby, St. Louis, p. 6.4-6.5.
Harlow and Lane. Antibodies, a Laboratory Manual, 1988, p. 140-243.
Morrison et al. “Complement activation and Fc receptor binding by IgG'”, Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, 1993, Mike Clark, Ed. pp. 101-113.
Schlom. “Monoclonal Antibodies: they're more and less than you think”, Molecular Foundations of Oncology, 1991, Samuel Broder, ed. pp. 95-134.
Gao et al. Aizheng, Oct. 2002, vol. 21, Abstract.
Green et al. Immunological Reviews, 2003, vol. 1993, pp. 70-81.
Euhus et al. Surgery, Gynecology and Obstetrics, 1992, vol. 175, Abstract.
White et al. Annu Rev Med 52:125-145, 2001.
Freshney, Culture of Animal Cells, a Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4.
Dermer, Bio/Technology 1994, 12:320.
Zips, in Vivo, 2005, 19:1-7.
Taber's Cyclopedic Medical Dictionary, 1985, F.A. Davis Company, Philadelphia, p. 274.
Busken, C. et al. Digestive Disease Week Abstracts and Itinerary Planner, 2003, abstract No. 850.
Kaiser, Science, 2006, 313,1370.
Krontiris and Capizzi, Internal Medicine, 4thEd., Editor-in-chief Jay Stein, Elsevier Science, 1994, Chapters 71-72, pp. 699-729.
Carter, S.K. et al. Chemotherapy of Cancer, 2ndEd., John Wiley & Sons: New York 1981, appendix C.
“Transcriptional factor purification utilizing protein to protein affinity,” Experimental Medicine, Supplementary Volume, Biomanual series 5, pp. 215-219 (published by Yodosha Co., Ltd.).
Dillman et al. “Therapy of Chronic Lymphocytic Leukemia and Cutaneous T-Cell Lymphoma with T101 Monoclonal Antibody,” Journal of Clinical Oncology, 2(8): 881-891, Aug. 1984.
Maecker et al. “The Tetraspanin Superfamiliy: Molecular Facilitators,” FASEB J. 11:428-442, May 1997.
Ritz et al. “Modulation of Human Acute Lymphoblastic Leukemia Antigen Induced by Monoclonal Antibody in Vitro,” Journal of Immunology, 125(4): 1506-1514, Oct. 1980.
Ritz et al. “Serotherapy of Acute Lymphoblastic Leukemia With Monoclonal Antibody”, Blood, 58(1): 141-152, Jul. 1981.
Schroff et al. “T65 Antigen Modulation in a Phase I Monoclonal Antibody Trial with Chronic Lymphocytic Leukemia Patients”, Journal of Immunology, 133(3): 1641-1648, Sep. 1984.
Shawler et al. “Induction of in Vitro and in Vivo Antigenic Modulation by the Anti-Human T-Cell Monoclonal Antibody T101”, Cancer Research, vol. 44, pp. 5921-5927, Dec. 1984.
Office Action dated Jun. 19, 2008, from co-pending U.S. Appl. No. 10/548,688.
Supplemental Office Action dated Oct. 2, 2008, from co-pending U.S. Appl. No. 10/548,688.
Applicant Response and Amendment dated Nov. 14, 2008, from co-pending U.S. Appl. No. 10/548,688.
Office Action dated Feb. 17, 2009, from co-pending U.S. Appl. No. 10/548,688.
Applicant Response and Amendment dated Apr. 15, 2009, from co-pending U.S. Appl. No. 10/548,688.
Office Action dated May 27, 2009, from co-pending U.S. Appl. No. 10/548,688.
Applicant Response and Amendment dated Nov. 20, 2009, from co-pending U.S. Appl. No. 10/548,688.
Office Action dated Oct. 31, 2006, from co-pending U.S. Appl. No. 11/223,812, now granted under Patent No. 7,361,340.
Applicant Reponse and Amendment dated Feb. 28, 2007 from co-pending U.S. Appl. No. 11/223,812, now granted under Patent No. 7,361,340.
Office Action dated Jun. 5, 2007, from co-pending U.S. Appl. No. 11/223,812, now granted under Patent No. 7,361,340.
Applicant Response and Amendment dated Sep. 5, 2007 from co-pending U.S. Appl. No. 11/223,812, now granted under Patent No. 7,361,340.
Office Action dated Mar. 18, 2008, from co-pending U.S. Appl. No. 11/345,651.
Applicant Response and Amendment dated Jul. 17, 2008, from co-pending U.S. Appl. No. 11/345,651.
Office Action dated Dec. 4, 2008, from co-pending U.S. Appl. No. 11/345,651.
Applicant Response and Amendment dated Feb. 27, 2009, from co-pending U.S. Appl. No. 11/345,651.
Office Action dated May 11, 2009, from co-pending U.S. Appl. No. 11/345,651.
Applicant Response and Amendment dated Sep. 11, 2009, from co-pending U.S. Appl. No. 11/345,651.
Final office action dated Dec. 4, 2009, in corresponding U.S. Appl. No. 11/345,651.
“Transcriptional factor purification utilizing protein to protein affinity,” Experimental Medicine, Supplementary Volume, Biomanual series 5, pp. 215-219 (published by Yodosha Co., Ltd.), 1996.
Agatsuma Toshinori
Fukuchi Keisuke
Hirai Takehiro
Ichikawa Kimihasa
Takahashi Shu
Canella Karen A
Dorsey & Whitney LLP
Sankyo Co. Ltd.
LandOfFree
Antibody against tumor specific antigen as target does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody against tumor specific antigen as target, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody against tumor specific antigen as target will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4204172